Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2004 May;75(5):689–695. doi: 10.1136/jnnp.2003.029868

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

P Pollak 1, F Tison 1, O Rascol 1, A Destee 1, J Pere 1, J Senard 1, F Durif 1, I Bourdeix 1
PMCID: PMC1763590  PMID: 15090561

Abstract

Objective: To compare the efficacy and safety of clozapine in drug induced psychosis in Parkinson's disease (PD).

Methods: A four week, randomised, double blind, parallel comparison of clozapine and placebo, followed by a 12 week clozapine open period, plus a one month period after drug discontinuation, in 60 patients with PD. The primary efficacy outcome was the "clinical global impression scale" (CGI); the positive subscore of the "positive and negative syndrome scale" (PANSS) was used as the secondary efficacy parameter and the "unified Parkinson's disease rating scale" (UPDRS) and the "mini mental test examination" (MMSE) as safety outcomes.

Results: The mean (SD) dosage of clozapine was 35.8 (12.5–50) mg at the end of the double blind period. The mean (SD) scores on the CGI improved by 1.8 (1.5) for the clozapine group compared with 0.6 (1.1) for the placebo group (p = 0.001). The mean (SD) positive subscore of PANSS improved by 5.6 (3.9) for the clozapine group (0.8 (2.8) for the placebo group; p < 0.0001). At the end of the open period, 25 patients had completely recovered from delusions and hallucinations, and 19 experienced a relapse within one month after the clozapine washout period. The UPDRS motor and MMSE mean scores did not change significantly in either group. Somnolence was more frequent with clozapine than with placebo.

Conclusions: Clozapine at a mean dose lower than 50 mg/day improves drug induced psychosis in PD without significant worsening of motor function, and the effect wears off once the treatment stops.

Full Text

The Full Text of this article is available as a PDF (449.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarsland D., Larsen J. P., Cummins J. L., Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol. 1999 May;56(5):595–601. doi: 10.1001/archneur.56.5.595. [DOI] [PubMed] [Google Scholar]
  2. Alvir J. M., Lieberman J. A., Safferman A. Z., Schwimmer J. L., Schaaf J. A. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993 Jul 15;329(3):162–167. doi: 10.1056/NEJM199307153290303. [DOI] [PubMed] [Google Scholar]
  3. Cummings J. L. Managing psychosis in patients with Parkinson's disease. N Engl J Med. 1999 Mar 11;340(10):801–803. doi: 10.1056/NEJM199903113401011. [DOI] [PubMed] [Google Scholar]
  4. Factor S. A., Molho E. S., Podskalny G. D., Brown D. Parkinson's disease: drug-induced psychiatric states. Adv Neurol. 1995;65:115–138. [PubMed] [Google Scholar]
  5. Folstein M. F., Folstein S. E., McHugh P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6. [DOI] [PubMed] [Google Scholar]
  6. Friedberg G., Zoldan J., Weizman A., Melamed E. Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol. 1998 Sep-Oct;21(5):280–284. [PubMed] [Google Scholar]
  7. Friedman J. H., Factor S. A. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 2000 Mar;15(2):201–211. doi: 10.1002/1531-8257(200003)15:2<201::aid-mds1001>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  8. Friedman J. H. The management of the levodopa psychoses. Clin Neuropharmacol. 1991 Aug;14(4):283–295. doi: 10.1097/00002826-199108000-00001. [DOI] [PubMed] [Google Scholar]
  9. Goetz C. G., Stebbins G. T. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology. 1995 Apr;45(4):669–671. doi: 10.1212/wnl.45.4.669. [DOI] [PubMed] [Google Scholar]
  10. Greene P., Cote L., Fahn S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neurol. 1993;60:703–706. [PubMed] [Google Scholar]
  11. Kay S. R., Opler L. A., Lindenmayer J. P. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl. 1989 Nov;(7):59–67. [PubMed] [Google Scholar]
  12. Melamed E., Friedberg G., Zoldan J. Psychosis: impact on the patient and family. Neurology. 1999;52(7 Suppl 3):S14–S16. [PubMed] [Google Scholar]
  13. Mosewich R. K., Rajput A. H., Shuaib A., Rozdilsky B., Ang L. Pulmonary embolism: an under-recognized yet frequent cause of death in parkinsonism. Mov Disord. 1994 May;9(3):350–352. doi: 10.1002/mds.870090316. [DOI] [PubMed] [Google Scholar]
  14. Pinter M. M., Helscher R. J. Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1993;5(2):135–146. doi: 10.1007/BF02251204. [DOI] [PubMed] [Google Scholar]
  15. Richard I. H., Nutt J. Worsening of motor function in Parkinson's disease: a "typical" response to "atypical" antipsychotic medications. Neurology. 2000 Sep 26;55(6):748–749. doi: 10.1212/wnl.55.6.748. [DOI] [PubMed] [Google Scholar]
  16. Rudolf J., Grond M., Neveling M., Heiss W. D. Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis. J Neural Transm (Vienna) 1997;104(11-12):1305–1311. doi: 10.1007/BF01294731. [DOI] [PubMed] [Google Scholar]
  17. Scholz E., Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci. 1985;235(1):60–64. doi: 10.1007/BF00380972. [DOI] [PubMed] [Google Scholar]
  18. Wagner M. L., Defilippi J. L., Menza M. A., Sage J. I. Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients. J Neuropsychiatry Clin Neurosci. 1996 Summer;8(3):276–280. doi: 10.1176/jnp.8.3.276. [DOI] [PubMed] [Google Scholar]
  19. Wolters E. C. Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment. Neurology. 1999;52(7 Suppl 3):S10–S13. [PubMed] [Google Scholar]
  20. Wolters E. C., Hurwitz T. A., Mak E., Teal P., Peppard F. R., Remick R., Calne S., Calne D. B. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology. 1990 May;40(5):832–834. doi: 10.1212/wnl.40.5.832. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES